Autophagy/Apoptosis Balance in Placental Vascular Pathologies
Study of the Autophagy/Apoptosis Balance in Placental Vascular Pathologies
Centre Hospitalier Universitaire de Nīmes
50 participants
May 2, 2025
OBSERVATIONAL
Conditions
Summary
Pregnancy increases the risk of thrombosis. Placenta-mediated diseases are a risk factor for cardiovascular pathologies and can lead to maternal-fetal morbidity and mortality. It is essential to understand the cellular and molecular mechanisms of dysfunctions at the vascular-placental interface so that systemic vascular risk can be characterized and, ultimately, screened for, on the basis of new markers (targeted preventive management). Deregulated autophagy could be the starting point for cell death by apoptosis or necrosis leading to complications. The pathophysiological mechanisms involved in trophoblast apoptosis are incompletely described. This project follows on from the GrossAuTop-1 study, which investigated the intra- and inter-individual variability of autophagy and apoptosis activities in women during pregnancy. The aim of this project is to study autophagy and apoptosis activities specifically in women developing a placental vascular complication during pregnancy.
Eligibility
Inclusion Criteria3
- Pregnant women developing a placental vascular complication (preeclampsia and/or intrauterine growth retardation), hospitalized and delivering at Nimes University Hospital.
- Pregnant woman with free and informed consent.
- Pregnant woman affiliated with and/or benefiting from a health insurance scheme.
Exclusion Criteria7
- Multiple pregnancy.
- Presence of hypertension and/or proteinuria prior to pregnancy.
- Participant in an interventional drug study.
- Persons in a period of exclusion determined by another study.
- Persons under court protection, guardianship or curatorship.
- Persons unable to give consent.
- Persons for whom it is impossible to give informed information.
Interventions
16 blood samples (16 tubes, i.e. 55.3 ml) will be taken at inclusion. Pregnant women will be seen every month as part of their pregnancy follow-up, and blood (11 tubes, i.e. 35.5 ml) and urine samples will be taken at each follow-up visit. At delivery, a systematic blood sample will be taken as part of the usual care, and an additional 11 tubes of blood (35.5 ml) will be taken.
Urine samples will be taken at the inclusion visit and at each follow-up visit.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06779916